{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:54:36Z","timestamp":1783727676887,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Regeneron Pharmaceuticals Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03049-8","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T08:40:21Z","timestamp":1733128821000},"page":"720-733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03992417","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Piergiacomo","family":"Calzavara-Pinton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Lapeere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia M.","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Fougerousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria S.","family":"Fomina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarmila","family":"\u010celakovsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Al-Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thrasyvoulos","family":"Tzellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwinten","family":"Bosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"issue":"4","key":"3049_CR1","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1111\/ijd.14763","volume":"59","author":"G Birdi","year":"2020","unstructured":"Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020;59(4):e75\u201391.","journal-title":"Int J Dermatol"},{"issue":"3","key":"3049_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZC Chiesa Fuxench","year":"2019","unstructured":"Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583\u201390.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"3049_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2017.04.019","volume":"77","author":"L Eckert","year":"2017","unstructured":"Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health\u2013related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-9.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3049_CR4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/all.13320","volume":"73","author":"K Abuabara","year":"2018","unstructured":"Abuabara K, Yu AM, Okhovat JP, Allen IE, Langan SM. The prevalence of atopic dermatitis beyond childhood: a systematic review and meta\u2013analysis of longitudinal studies. Allergy. 2018;73(3):696\u2013704.","journal-title":"Allergy"},{"issue":"4","key":"3049_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/all.12112","volume":"68","author":"D Garmhausen","year":"2013","unstructured":"Garmhausen D, Hagemann T, Bieber T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013;68(4):498\u2013506.","journal-title":"Allergy"},{"issue":"12","key":"3049_CR6","doi-asserted-by":"publisher","first-page":"adv0160","DOI":"10.2340\/00015555-3510","volume":"100","author":"S Bylund","year":"2020","unstructured":"Bylund S, Kobyletzki LB, Svalstedt M, Svensson \u00c5. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv0160.","journal-title":"Acta Derm Venereol"},{"issue":"10023","key":"3049_CR7","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109\u201322.","journal-title":"Lancet"},{"issue":"10247","key":"3049_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"1","key":"3049_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3049_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337.","journal-title":"Expert Rev Clin Immunol"},{"issue":"14","key":"3049_CR11","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111(14):5147\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"3049_CR12","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111(14):5153\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"3049_CR13","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floch","year":"2020","unstructured":"Le Floch A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204.","journal-title":"Allergy"},{"issue":"10013","key":"3049_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","volume":"387","author":"D Tha\u00e7i","year":"2016","unstructured":"Tha\u00e7i D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40\u201352.","journal-title":"Lancet"},{"issue":"24","key":"3049_CR15","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, SOLO 1 and SOLO 2 Investigators, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"3049_CR16","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","volume":"75","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Gadkari A, Worm M, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2016;75(3):506\u201315.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3049_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s13555-017-0181-6","volume":"7","author":"EL Simpson","year":"2017","unstructured":"Simpson EL. Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase 3 clinical trials. Dermatol Ther (Heidelb). 2017;7(2):243\u20138.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"3049_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2020","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377\u201388.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3049_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44\u201356.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"3049_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/bjd.18476","volume":"182","author":"MJ Cork","year":"2020","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020;182(1):85\u201396.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3049_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaci.2018.11.006","volume":"143","author":"AS Paller","year":"2019","unstructured":"Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46\u201355.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3049_CR22","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/bjd.19460","volume":"184","author":"MJ Cork","year":"2021","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged \u2265 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2021;184(5):857\u201370.","journal-title":"Br J Dermatol"},{"issue":"12","key":"3049_CR23","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.1007\/s12325-023-02644-5","volume":"40","author":"P Calzavara-Pinton","year":"2023","unstructured":"Calzavara-Pinton P, \u010celakovsk\u00e1 J, Lapeere H, et al. Baseline demographics, comorbidities, treatment patterns and burden of atopic dermatitis in adults and adolescents from the GLOBOSTAD long-term observational study. Adv Ther. 2023;40(12):5366\u201382.","journal-title":"Adv Ther"},{"issue":"1","key":"3049_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","volume":"67","author":"ME Schram","year":"2012","unstructured":"Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99\u2013106.","journal-title":"Allergy"},{"issue":"1","key":"3049_CR25","doi-asserted-by":"publisher","first-page":"2216322","DOI":"10.1080\/09546634.2023.2216322","volume":"34","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, Bieber T, Kleyn CE, et al. Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis. J Dermatol Treat. 2023;34(1):2216322.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"3049_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27\u201333.","journal-title":"Dermatology"},{"issue":"1","key":"3049_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/pde.15134","volume":"40","author":"T McPherson","year":"2023","unstructured":"McPherson T, Cork MJ, Goodhead C, et al. A real-world retrospective observational study exploring NHS resource use in England for the management of moderate-to-severe atopic dermatitis in secondary care for children and adolescents. Pediatr Dermatol. 2023;40(1):50\u201363.","journal-title":"Pediatr Dermatol"},{"issue":"6 Suppl 1","key":"3049_CR28","first-page":"AB93","volume":"76","author":"EL Simpson","year":"2017","unstructured":"Simpson EL, Beck LA, Gadkari A, Eckert L, Reaney M. Defining a responder on the Peak Pruritus Numerical Rating Scale (NRS) in patients with moderate-to-severe atopic dermatitis: detailed analysis from randomized trials of dupilumab. J Am Acad Dermatol. 2017;76(6 Suppl 1):AB93.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3049_CR29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.otohns.2010.05.007","volume":"143","author":"JT Rich","year":"2010","unstructured":"Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg. 2010;143(3):331\u20136.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"3049_CR30","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","volume":"94","author":"D Tha\u00e7i","year":"2019","unstructured":"Tha\u00e7i D, Simpson EL, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266\u201375.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"3049_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s13555-023-01061-4","volume":"14","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Lockshin B, Lee LW, Chen Z, Daoud M, Korotzer A. Real-world effectiveness of dupilumab in adult and adolescent patients with atopic dermatitis: 2-year interim data from the PROSE registry. Dermatol Ther (Heidelb). 2024;14(1):261\u201370.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"3049_CR32","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1080\/09546634.2022.2038361","volume":"33","author":"M de Bruin-Weller","year":"2022","unstructured":"de Bruin-Weller M, Pink AE, Ferrucci SM, et al. Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD). J Dermatol Treat. 2022;33(5):2565\u201370.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"3049_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.anai.2020.07.026","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Guttman-Yassky E, Gadkari A, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):40\u20135.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03049-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03049-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03049-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:52:19Z","timestamp":1738407139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03049-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3049"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03049-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P. Calzavara-Pinton is an advisory board member for AbbVie, Almirall, Galderma, LEO Pharma, Meda, and Sanofi. C-Y. Chu is an investigator for AbbVie, Dermira, Eli Lilly, Novartis, Oneness Biotech, Pfizer, Regeneron Pharmaceuticals Inc., Roche, and Sanofi; a consultant for AbbVie, Eli Lilly, Novartis, Pfizer, Roche, and Sanofi; a speaker for AbbVie, Eli Lilly, Mylan, Novartis, Pfizer, Roche, Sanofi, and Viatris; and an advisory board member for Mylan, Pfizer, Roche, and Sanofi. Hilde Lapeere is on the advisory boards of AbbVie, LEO Pharma, Eli Lilly, Pfizer, and Sanofi. M. Rossi is a speaker for AbbVie, Galderma, La Roche-Posay, LEO Pharma, Pfizer, and Sanofi. S.M. Ferrucci is an advisory board member for AbbVie, Eli Lilly, and Sanofi; a principal Investigator for Almirall, Menarini, and Pfizer; and reports honoraria for lectures and research grants from Novartis. W-H. Chung has nothing to disclose. A-C. Fougerousse is a consultant for AbbVie, Galderma, LEO Pharma, Lilly, and Sanofi; and a consultant for AbbVie, Eli Lilly, and Sanofi. D.S. Fomina reports honoraria from CSL Behring, Novartis, Sanofi, and Shire. G.\u00a0Holzer is an advisory board member for AbbVie, Almirall, Eli Lilly, Galderma, LEO Pharma, and Sanofi. J. \u010celakovsk\u00e1 has nothing to disclose. M. Al-Ahmad is an advisory board member and speaker for AstraZeneca, GSK, and Novartis. T. Tzellos has received honoraria from and is an advisory board member and speaker for AbbVie; and has received honoraria from and is an advisory board member for Boehringer Ingelheim and Sanofi. J. Wu is an employee of Sanofi, and may hold stock and\/or stock options in the company. M. Ardeleanu is an employee and shareholder of Regeneron Pharmaceuticals Inc. K. Bosman is an employee and shareholder of Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline and applicable regulatory requirements. The local institutional review board or ethics committee at each study center oversaw trial conduct and documentation. All patients, or their parents\/guardians, provided written informed consent before participating in the trial. Pediatric patients provided assent according to the ethics committee (institutional review board\/independent ethics committee)-approved standard practice for pediatric patients at each participating center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}